Jazz Pharmaceuticals vs Sarepta Therapeutics
JAZZ and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and SRPT compare
Jazz Pharmaceuticals is the larger company, worth 7.1 times as much as Sarepta Therapeutics ($14.0B against $2.0B).
Jazz Pharmaceuticals grew revenue faster over the last twelve months (12.6% versus −20.4% for Sarepta Therapeutics).
Jazz Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −6.9% at Sarepta Therapeutics.
Sarepta Therapeutics scores higher on the StockData Score (12 against 11 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $14.0B | $2.0B |
| Share price | $215.98 | $18.62 |
| Change, 1 year | 59.1% | −20.6% |
| Change, 5 years | 59.9% | −79.1% |
| Beta (5Y) | 0.55 | 1.02 |
| Employees | 2,890 | 835 |
| StockData Score | ||
| Total score | 11 | 12 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 1 | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.8× | – |
| P/S | 3.0× | 1.0× (better) |
| P/B | 2.9× | 1.3× (better) |
| EV/EBITDA | 18.0× | – |
| P/FCF | 8.8× (better) | 24.0× |
| FCF yield | 11.4% (better) | 4.2% |
| Fair value | $254.92 | $109.03 |
| Margin of safety | 15.3% | 82.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.6% (better) | −20.4% |
| Revenue growth, 5Y average | 12.5% | 32.4% (better) |
| Profitability | ||
| Operating margin | 19.5% (better) | −7.3% |
| Net margin | 20.4% (better) | −6.9% |
| FCF margin | 34.6% (better) | 4.1% |
| Return on equity | 22.1% (better) | −9.3% |
| Return on invested capital | 12.1% (better) | −16.8% |
| Financial health | ||
| Debt / equity | 0.91 (better) | 0.00 |
| Net debt / EBITDA | 2.40 | – |
| Current ratio | 1.78 | 4.42 (better) |
| Altman Z-score | 2.35 (better) | −0.17 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.2% | 102% |
| Held by insiders | 3.4% | 5.9% |
| Insider net buying, 12 months | −$68.0M | −$417K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.7% | 22.9% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.